An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis-Reference-Cited by-同舟云学术

An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis

Published:2023-12-10 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Eyerich K.¹²^ORCID,Krueger J.³,Stahle M.¹,Schakel K.⁴^ORCID,Conrad C.⁵^ORCID,Armstrong A.⁶,Gniadecki R.⁷,Puig L.⁸^ORCID,Scoble T.⁹,Williams N.⁹

Affiliation:

1. Karolinska Institute Solna Sweden

2. University of Freiburg Breisgau Germany

3. The Rockefeller University Hospital New York New York USA

4. Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases Heidelberg University Hospital Heidelberg Germany

5. Lausanne University Hospital Lausanne Switzerland

6. University of Southern California Los Angeles California USA

7. University of Alberta Edmonton Alberta Canada

8. Autonomous University of Barcelona Bellaterra Spain

9. Triducive Partners Limited Royal Tunbridge Wells UK

Funder

Janssen Pharmaceuticals

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.19652

Reference10 articles.

1. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

2. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

3. National Institute for Health and Care Excellence (NICE).Psoriasis: Assessment and Management (CG153) 2017. Available from:https://www.nice.org.uk/guidance/cg153(last accessed 5 September 2023).

4. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

5. Concept of Remission in Chronic Plaque Psoriasis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis;JAMA Dermatology;2024-07-31